Medullary thyroid carcinoma in ethnic Chinese with MEN2A: A case report and literature review


      Medullary Thyroid Carcinoma (MTC) is the most common cause of death in MEN patients.
      It is curative by prophylactic total thyroidectomy, but controversies remain as to the optimal timing for prophylactic thyroidectomy. The current recommendation is for prophylactic total thyroidectomy before age 5, but a recent study suggested that in the ethnic Chinese, even “high risk” mutations did not result in early malignant change, and it was suggested that prophylactic thyroidectomy may be performed at a later age. We report a case of an ethnic Chinese girl with MEN2A codon 634 (C634R) mutation, whose operative specimen at prophylactic thyroidectomy at 4 years 8 months showed MTC. We advocate that management of MEN2A patients should be codon-directed, regardless of ethnicity.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Pediatric Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Brandi M.L.
        • Gagel R.F.
        • Angeli A.
        • et al.
        Guidelines for diagnosis and therapy of MEN type 1 and type 2.
        J Clin Endocrinol Metab. 2001; 86: 5658-5671
        • Skinner M.A.
        • Moley J.A.
        • Dilley W.G.
        • et al.
        Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A.
        N Engl J Med. 2005; 353: 1105-1113
        • Schreinemakers J.M.J.
        • Vriens M.R.
        • Valk G.D.
        • et al.
        Factors predicting outcome of total thyroidectomy in young patients with multiple endocrine neoplasia type 2: a nationwide long-term follow-up study.
        World J Surg. 2010; 34: 852-860
        • Kloos R.T.
        • Eng C.
        • Evans D.B.
        • et al.
        Medullary thyroid cancer: management guidelines of the American Thyroid Association.
        Thyroid. 2009; 19: 565-612
        • Lau G.S.K.
        • Lang B.H.H.
        • Lo C.Y.
        • et al.
        Prophylactic thyroidectomy in ethnic Chinese patients with multiple endocrine neoplasia type 2A syndrome after the introduction of genetic testing.
        Hong Kong Med J. 2009; 15: 326-331
        • Guyetant S.
        • Dupre F.
        • Bigorgne J.C.
        • et al.
        Medullary thyroid microcarcinoma: a clinicopathologic retrospective study of 38 patients with no prior familial disease.
        Hum Pathol. 1999; 30: 957-963
        • Machens A.
        • Dralle H.
        Multiple endocrine neoplasia type 2: achievements and current challenges.
        Clinics (Sao Paulo). 2012; 67: 113-118
        • Wells Jr., S.A.
        • Robinson B.G.
        • Gagel R.F.
        • et al.
        Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
        J Clin Oncol. 2012; 30: 134-141
        • Bargren A.E.
        • Meyer-Rochow G.Y.
        • Delbridge L.W.
        • et al.
        Outcomes of surgically managed pediatric thyroid cancer.
        J Surg Res. 2009; 156: 70-73
        • Bugalho M.J.
        • Dominques R.
        • Santos J.R.
        • et al.
        Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre.
        Surgery. 2007; 141: 90-95
        • Sosa J.A.
        • Tuggle C.T.
        • Wang T.S.
        • et al.
        Clinical and economic outcomes of thyroid and parathyroid surgery in children.
        J Clin Endocrinol Metab. 2008; 93: 3058-5865
        • Sakorafas G.H.
        • Friess H.
        • Peros G.
        The genetic basis of hereditary medullary thyroid cancer: clinical implications for the surgeon, with a particular emphasis on the role of prophylactic thyroidectomy.
        Endocr Relat Cancer. 2008; 15: 871-884
        • Hanukoglu A.
        • Perlman K.
        • Shamis I.
        • et al.
        Relationship of etiology to treatment in congenital hypothyroidism.
        J Clin Endocrinol Metab. 2001; 86: 186-191
        • Takahashi M.
        • Ritz J.
        • Cooper G.M.
        Activation of a novel human transforming gene, ret, by DNA rearrangement.
        Cell. 1985; 42: 581-588
        • Romeo G.
        • Ronchetto P.
        • Luo Y.
        • et al.
        Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease.
        Nature. 1994; 367: 377-378
        • Cote G.J.
        • Gagel R.F.
        Lessons learned from the management of a rare genetic cancer.
        N Engl J Med. 2003; 349: 1566-1568
        • Machens A.
        • Gimm O.
        • Hinze R.
        • et al.
        Genotype–phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties.
        J Clin Endocrinol Metab. 2001; 86: 1104-1109
        • Puñales M.K.
        • Graf H.
        • Gross J.L.
        • et al.
        RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome.
        J Clin Endocrinol Metab. 2003; 88: 2644-2649
        • Gill J.R.
        • Reyes-Múgica M.
        • Iyengar S.
        • et al.
        Early presentation of metastatic medullary carcinoma in multiple endocrine neoplasia, type IIA: implications for therapy.
        J Pediatr. 1996; 129: 459-464
        • Zhou Y.
        • Zhao Y.
        • Cui B.
        • et al.
        RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland Chinese familes with MEN2A and MEN2B.
        Clin Endocrinol (Oxf). 2007; 67: 507-576
        • Machens A.
        • Lorenz K.
        • Dralle H.
        Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels.
        Ann Surg. 2009; 250: 305-310